Latest & greatest articles for ezetimibe

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ezetimibe or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ezetimibe and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ezetimibe

1. Ezetimibe

Ezetimibe Top results for ezetimibe - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ezetimibe The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Ezetimibe and ezetimibe/simvastatin for primary hypercholesterolaemia

Ezetimibe and ezetimibe/simvastatin for primary hypercholesterolaemia '); } else { document.write(' '); } ACE | Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia Search > > Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia - Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Ezetimibe 10 mg tablet (...) Ezetimibe 10 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications. SDL subsidy does not apply to ezetimibe/simvastatin 10/10 mg or 10/20 mg tablets. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

3. Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons

Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00481351 Recruitment Status : Completed First Posted : June 1, 2007 Results First Posted : January 26, 2011 Last Update Posted : January 26, 2011 Sponsor

2007 Clinical Trials

4. Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease

Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Azetidines; Coronary Diseases; Drug Combinations; Simvastatin Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning

2013 Health Technology Assessment (HTA) Database.

5. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. Limited evidence is available regarding the benefit and hazard of higher-intensity treatment to lower lipid levels among patients 75 years or older. As a result, guideline recommendations differ for this age group compared with younger patients.To determine the effect on outcomes and risks of combination (...) ezetimibe and simvastatin compared with simvastatin monotherapy to lower lipid levels among patients 75 years or older with stabilized acute coronary syndrome (ACS).In this prespecified secondary analysis of the global, multicenter, prospective clinical randomized Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), outcomes and risks were compared by age among patients 50 years or older after a hospitalization for ACS. Data were collected from October 26, 2005, through

2019 JAMA cardiology Controlled trial quality: predicted high

6. LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs

LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs LIPTRUZET SUMMARY CT14103

2016 Haute Autorite de sante

7. IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin?

IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin? RxFiles: Trial Summary www.RxFiles.ca - Dec 2014, Updated June 2015 Loren Regier BSP BA, Brent Jensen BSP IMPROVE-IT To add, or not to add ezetimibe EZETROL to moderate dose statin? What we already knew? ? Statins… have consistently demonstrated efficacy in lowering not only LDL, but risk of cardiovascular (CV) events +/- mortality in those with high CV risk. 1 ? Ezetimibe… 2 o has no evidence as monotherapy (...) -controlled trial design, the benefit could have been due to the statin alone. SHARP What IMPROVE-IT may add? ? Ezetimibe may modestly lower CV event risk when added to a moderate dose statin (simvastatin 40mg). IMPROVE-IT 3,4 n=18,144; stable-recent ACS, normal LDL median2.46 ? 1.4 vs 1.8mmol/L Ezetimibe 10mg +Simvastatin 40mg Simvastatin 40mg NNT P Comment Combination VYTORIN USA only used. Composite of CV death, MI, unstable angina requiring hospitalization, revascularization or stroke (1 ? Endpoint

2014 RxFiles

8. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Full Text available with Trip Pro

Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Patients who experience an acute coronary syndrome are at heightened risk of recurrent ischemic events, including stroke. Ezetimibe improved cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary syndrome. We investigated the efficacy of the addition (...) of ezetimibe to simvastatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), with a focus on patients with a stroke before randomization.Patients who experienced acute coronary syndrome were randomized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followed for a median of 6 years. Treatment efficacy was assessed for the entire population and by subgroups for the first and total (first

2018 EvidenceUpdates

9. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 (...) days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial

2015 NEJM Controlled trial quality: predicted high

10. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J CRD summary This well-conducted review concluded that ezetimibe alone or in combination with a statin was effective (...) in reducing low density lipoprotein cholesterol in short-term studies. When used alone, ezetimibe is less effective than statins. The authors' conclusions reflect the evidence and their recommendations for research appear appropriate given the lack of long-term data in the included studies. Authors' objectives To review the clinical and cost-effectiveness of ezetimibe for treatment of primary hypercholesterolaemia. Searching Twelve electronic databases were searched from inception to June 2006. Search

2008 DARE.

11. Ezetimibe for the prevention of cardiovascular Events

Ezetimibe for the prevention of cardiovascular Events 1 Translation of the executive summary of the rapid report A18-83 Ezetimib zur Prävention kardiovaskulärer Ereignisse (Version 2.0; Status: 3 September 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A18-83 Ezetimibe for the prevention of cardiovascular events 1 (...) Extract of rapid report A18-83 Version 2.0 Ezetimibe for the prevention of cardiovascular events 3 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ezetimibe for the prevention of cardiovascular events Commissioning agency: Federal Joint Committee Commission awarded on: 22 November 2018 Internal Commission No.: A18-83 Address of publisher: Institut für Qualität und

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Full Text available with Trip Pro

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. The aim of this study was to evaluate the low-density lipoprotein cholesterol lowering efficacy and safety of a bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination in patients with hypercholesterolemia and a high risk of cardiovascular disease receiving maximally tolerated statin therapy.This phase 3, double-blind clinical (...) trial enrolled adult patients at high risk of cardiovascular disease due to atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or multiple cardiovascular disease risk factors. Patients were randomly assigned (2:2:2:1) to treatment with the fixed-dose combination, bempedoic acid 180 mg, ezetimibe 10 mg or placebo added to stable background statin therapy for 12 weeks. The primary efficacy endpoint was the percentage change from baseline to week 12 in low-density

2019 European journal of preventive cardiology Controlled trial quality: predicted high

13. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia Ezetimibe for treating primary Ezetimibe for treating primary heterozygous-familial and non-familial heterozygous-familial and non-familial h hypercholesterolaemia ypercholesterolaemia T echnology appraisal guidance Published: 24 February 2016 nice.org.uk/guidance/ta385 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

14. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Full Text available with Trip Pro

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. The apolipoprotein B/A1 (apoB/A1) ratio is a stronger predictor of future cardiovascular disease than is the level of conventional lipids. Statin and ezetimibe combination therapy have shown additional cardioprotective effects over statin monotherapy.This was a single-center, randomized, open-label, active (...) -controlled study in Korea. A total of 36 patients with type 2 diabetes mellitus were randomized to either rosuvastatin monotherapy (20 mg/day, n=20) or rosuvastatin/ezetimibe (5 mg/10 mg/day, n=16) combination therapy for 6 weeks.After the 6-week treatment, low density lipoprotein cholesterol (LDL-C) and apoB reduction were comparable between the two groups (-94.3±15.4 and -62.0±20.9 mg/dL in the rosuvastatin group, -89.9±22.7 and -66.8±21.6 mg/dL in the rosuvastatin/ezetimibe group, P=0.54 and P=0.86

2019 Diabetes & metabolism journal Controlled trial quality: uncertain

15. Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. (Abstract)

Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Evolocumab and ezetimibe, were both proven to significantly reduce the incidence of major adverse cardiovascular events (MACE), in type 2 diabetes patients with atherosclerotic cardiovascular disease and low-density lipoprotein (LDL) cholesterol >70 mg/dl despite statin therapy. Providing evolocumab for all such patients may be a significant (...) burden on healthcare systems. Therefore, we analyzed the treatment cost of ezetimibe versus evolocumab to prevent 1 MACE. We extracted the number needed to treat (NNT) with evolocumab or with ezetimibe for avoiding MACE from the published FOURIER and IMPROVE-IT trials respectively. Drug costs were based on 2018 US prices. Sensitivity and scenario analyses were performed to overcome variances in terms of population risk, efficacy of therapies, and costs. In FOURIER, the 1-year NNT for avoiding MACE

2019 American Journal of Cardiology

16. Ezetimibe

Ezetimibe Ezetimibe Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Ezetimibe Ezetimibe Aka: Ezetimibe , Zetia , Vytorin , Liptruzet (...) (10/40) instead of alone for 7 years (2015) Presc Lett 22(1): 2 Enhance Study Found that Vytorin is not more effective than alone Despite LDL lowering, did not further slow atherosclerosis Casts doubt on Ezetimibe (Zetia) benefit, but further trials are needed Initial Data levels did not change significantly reduced 17% increased 1.3% Postulated reason for lack of effect in coronary event prevention despite LDL lowering Scavenger Receptor B1 inhibition appears to be the mechanism for this lack

2018 FP Notebook

17. Quantitation of the Rates of Hepatic and Intestinal Cholesterol Synthesis in Lysosomal Acid Lipase-Deficient Mice Before and During Treatment with Ezetimibe Full Text available with Trip Pro

Quantitation of the Rates of Hepatic and Intestinal Cholesterol Synthesis in Lysosomal Acid Lipase-Deficient Mice Before and During Treatment with Ezetimibe Esterified cholesterol (EC) and triglycerides, contained within lipoproteins taken up by cells, are hydrolysed by lysosomal acid lipase (LAL) in the late endosomal/lysosomal (E/L) compartment. The resulting unesterified cholesterol (UC) is transported via Niemann-Pick type C2 and C1 into the cytosolic compartment where it enters a putative (...) with treatments that disrupt the enterohepatic movement of cholesterol or bile acids. Here we measured rates of cholesterol synthesis in vivo in the liver and small intestine of a mouse model for CESD given the cholesterol absorption inhibitor ezetimibe from weaning until early adulthood. Consistent with previous findings, this treatment significantly reduced the amount of EC sequestered in the liver (from 132.43±7.35 to 70.07±6.04mg/organ) and small intestine (from 2.78±0.21 to 1.34±0.09mg/organ) in the LAL

2017 Biochemical pharmacology

18. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Full Text available with Trip Pro

Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) showed that adding the nonstatin ezetimibe to statin therapy further reduced cardiovascular events in patients after an acute coronary syndrome. In a prespecified analysis, we explore results stratified by sex.In IMPROVE-IT, patients (...) with acute coronary syndrome and low-density lipoprotein cholesterol of 50 to 125 mg/dL were randomized to placebo/simvastatin 40 mg or ezetimibe/simvastatin 10/40 mg. They were followed up for a median of 6 years for the primary composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina, coronary revascularization ≥30 days, and stroke. Among 18 144 patients in IMPROVE-IT, 4416 (24%) were women. At 12 months, the addition of ezetimibe to simvastatin significantly

2017 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease Controlled trial quality: predicted high

19. Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency Full Text available with Trip Pro

Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency Lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from Wolman Disease to Cholesterol Ester Storage Disease. Recently enzyme replacement therapy with sebelipase alpha has been approved by drug agencies for treatment of this lysosomal disease. Ezetimibe is an azetidine derivative which blocks (...) Niemann Pick C1-Like 1 Protein; as its consequence, plasmatic concentration of low density lipoproteins and other apoB-containing lipoproteins, that are the substrate of lysosomal acid lipase, are decreased. Furthermore, ezetimibe acts by blocking inflammasome activation which is the cause of liver fibrosis in steatohepatitis and in lysosomal storage diseases.Two patients with Cholesterol Ester Storage Disease were treated with ezetimibe for 9 years and a third patients for 10 years. Treatment

2018 Orphanet journal of rare diseases

20. Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Full Text available with Trip Pro

Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. Objective Compared the effect of atorvastatin 10 mg combined ezetimibe 10 mg therapy with atorvastatin 20 mg on the long-term outcomes in very elderly patients with acute coronary syndrome.Methods A total of 230 octogenarian patients with acute coronary syndrome underwent coronary angiography were randomized to combined therapy group (atorvastatin 10 mg (...) /d and ezetimibe 10 mg/d, n=114) or double-dose atorvastatin group (atorvastatin 20mg/d, n=116). The primary end point was one-year incidence of major adverse cardiovascular events (including cardiac death, spontaneous myocardial infarction, unplanned revascularization).Result At the end of one year, the percentage of patients with low-density lipoprotein cholesterol level decreased more than 30% or 50% were comparable between the two groups (93.5% vs. 90.1%, p= 0.36; 54.6% vs. 49.6%, p= 0.45

2017 Oncotarget Controlled trial quality: uncertain